ClinicalTrials.gg
CompletedNCT04082416Updated May 11, 2023

Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)

A Phase 3 interventional study of Placebo plus standard therapy and RC18 160 mg plus standard therapy in Systemic Lupus Erythematosus, sponsored by RemeGen Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-05-11.

Sponsored by RemeGen Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
335
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing telitacicept in Lupus Erythematosus, Systemic — 6 open to participants now, 7 under way, 1 of them phase 3. telitacicept · Lupus Erythematosus, Systemic.

Enrollment
Largest of 13
335 · median 64
Started
2019
the only one that year
Phase 3
4 of 13
1 open now
Registered
2nd of 13
by date
Lead sponsor
4 of 13
RemeGen Co., Ltd.

Among the 13 studies testing telitacicept in Lupus Erythematosus, Systemic, this one has the largest enrollment, is the only one that started in 2019, is one of 4 in phase 3, and was the 2nd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

6 of the 13 studies testing telitacicept in Lupus Erythematosus, Systemic are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About telitacicept

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing telitacicept in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to initially access the safety and effectivity of RC18 combined with standard treatment and Placebo combined with standard therapy in subjects with Moderate to severe SLE.

03

Conditions studied

  • Systemic Lupus Erythematosus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Active SLE disease#and at least according with 4 of the 11 items of the American College of Rheumatology (ACR) criteria 1997.
  • Age \& Gender: Male or female between 18 and 65 years of age inclusive#and the sex ratio is not limited
  • Signed form#willing or able to participate in all required study evaluations and procedures.
  • SELENA-SLEDAI(Safety of Estrogens in Lupus Erythematosus National Assessment SLE Disease Activity Index) score ≥ 8 during the screening period.and if there is Hypo-complement or the Anti-dsDNA score, SELENA-SLEDAI disease activity score should be at least 6 at screening .
  • Autoantibody-positive
  • on a stable SLE treatment regimen for at least 30 days prior to Day 1, which consisted of any of the following (alone or in combination): cortical hormone,anti-malarials,non-steroidal anti inflammatory drugs (NSAIDs),or any and immunomodulator therapy(i.e.,azathioprine,mycophenolate

Exclusion criteria

Exclusion Criteria:

  • kidney disease :Severe lupus nephritis 8 weeks prior to randomization (designed as:Urine protein>6g/24h or serum creatinine ( SCr>2.5mg/dL or 221umol/L ) or needing for hemodialysis or receipting high dose cortical hormone ≥14 days( metacortandracin>100mg/d or equivalent)
  • Central nervous system disease caused by SLE or non SLE 8 weeks prior to randomization (including epilepsy、 mental disease、organic encephalopathy syndrome、cerebrovascular accident, encephalitis, central nervous system vasculitis;
  • there are serious heart, liver, kidney and other important organs and blood, endocrine system diseases and medical history;

Evaluation criteria for severity :

  1. #ALT#or aspartate aminotransferase (AST) ≥2 (ULN);
  2. (Ccr)\<30ml/min;
  3. White Blood Cell Count(WBCs)\<2.5x 10(9)/L;
  4. \<85g/L;
  5. \<50x 10(9)/L.

    • Have a historically active hepatitis or active hepatitis or medical history, :Patients with positive HBsAg are excluded.;: Patients with hepatitis C antibody positive are excluded;
    • Immune deficiency, uncontrolled severe infection and patients with active or recurrent peptic ulcer;
    • Pregnant , lactating women and men or women who have birth plans in the past 12 months ;
    • Have a history of allergic reaction to human biological medicines.
    • Receipt of within 1 month;
    • Have participated in any clinical trial in the first 28 days of the initial screening or 5 times half-life period of the study compound (taking the time for the elderly).
    • Have received treatment with B cell targeted therapy such as Rituximab or Epratuzumab etc.
    • Receipt of anti-tumor necrosis factor#interleukin receptor antagonist#
    • Receipt of IV immunoglobulin(IVIG),prednisone>100mg/d more than 14 days or plasma exchange;
    • There are active infections (such as herpes zoster, (HIV) virus infection, active tuberculosis, etc.) during the screening period;
    • Patients have depression or the significant suicide ideation;
    • Interleukin(IL)-2, thalidomide, Tripterygium wilfordii and traditional Chinese medicine preparation containing Tripterygium Wilfordii were used within 28 days before randomization
    • Investigator considers candidates not appropriating for the study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
335 participants (actual)

Study arms

  • Experimental
    RC18 160mg

    Patients received the test group RC18 160mg weekly administered subcutaneously for 52 times.

    Biological: RC18 160 mg plus standard therapy

  • Placebo comparator
    Placebo

    Patients received the test group Placebo weekly administered subcutaneously for 52 times.

    Biological: Placebo plus standard therapy

Interventions

  • BiologicalPlacebo plus standard therapy

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )

    Also known as: Standard therapy

  • BiologicalRC18 160 mg plus standard therapy

    Drug page: Telitacicept

    Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,Tacrolimus ,ciclosporin )

    Also known as: Standard therapy

06

What researchers measure

Primary outcomes

  1. SLE Responder Index (SRI) Response Rate

    At Week 52 the percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score and increasing no more than 0.3 points in PGA and no new BILAG A organ domain score or 1 new BILAG B organ domain scores compared with baseline at the time of assessment

    Time frame: Week 52

Secondary outcomes

  1. Percent of subjects with ≥ 4 point reduction from baseline in SELENA-SLEDAI score

    Time frame: Week 52

  2. Mean Change From Baseline in Physician's global assessment(PGA)

    Physician's global assessment, PGA.The measurement tool is Visual Analogue Scale/Score(VAS).The doctor assesses participant's disease activity on a VAS of 0-100 mm on the questionnaire form.The higher values represent a worse outcome.There are not combined subscales.

    Time frame: Week 52

  3. Percent of Subjects Whose Average Prednisone Dose Has Been Reduced by ≥ 25% From Baseline or ≤ 7.5 mg/Day,During Weeks 44 Through 52.

    Time frame: Week 44 through 52

  4. Mean Change From Baseline in Serological Examination Index

    Time frame: week 52

  5. The flare time after randomization

    Time frame: 52 weeks

07

Study locations

1 site
  • Remegen,ltd.
    Yantai, Shandong, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Apr 2022, 30 months.

Of 53 phase 3 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 84. This study's 30 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2019
First posted
Sep 9, 2019
StartActual
Oct 16, 2019
Primary completionActual
Apr 24, 2022
CompletionActual
Jun 30, 2022
Last update
May 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04082416
Lead sponsor
RemeGen Co., Ltd.
Responsible party
Sponsor
First posted
Sep 9, 2019
Start date
Oct 16, 2019
Primary completion
Apr 24, 2022
Completion
Jun 30, 2022
Last update
May 11, 2023

Study contacts

Fengchun Zhang, M.D.
principal investigator · Peking Union Medical College Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telitacicept

Start the discussion